What are the indications and contraindications for using platinib?

Pralsetinib is a highly selective RET inhibitor. As a targeted therapy, it plays an increasingly important role in the treatment of malignant tumors such as non-small cell lung cancer (NSCLC) and thyroid cancer. This drug mainly interferes with the proliferation and survival of tumor cells by inhibiting the signaling pathways caused by RET gene fusion or activation mutations. Understanding its indications and contraindications is crucial for clinical use and patient safety.

In terms of indications, platinib has been approved by the U.S. FDA and many countries for the treatment of patients with non-small cell lung cancer (NSCLC) carrying RET gene fusions, especially for locally advanced or metastatic cases. In addition, it is an important treatment option for patients with RET mutation-positive medullary thyroid carcinoma (MTC), especially when radioactive iodine therapy fails or is ineffective. Some countries or regions also use it in the case management of RET fusion-positive anaplastic thyroid cancer or other solid tumors, reflecting the broad-spectrum potential of this drug in the treatment of RET-driven tumors.

However, platinib is not suitable for all patients. In terms of contraindications, first of all, those who are allergic to the active ingredient of Platinib or any of its excipients should be strictly prohibited from using it. Secondly, patients with severe hepatic impairment or uncontrolled cardiovascular disease should be used after careful evaluation. Because this drug may have certain effects on liver enzymes, blood pressure, and lung function, people with active interstitial lung disease or a history of drug-induced pneumonia should use it with special caution.

In addition, women of childbearing age must take effective contraceptive measures while using platinib because it may affect fetal development. Breastfeeding women should also suspend breastfeeding as it is unknown whether the drug is excreted in breast milk, but it is recommended to avoid breastfeeding due to potential toxicity.

Reference: https://gavreto.com/